Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Martin, M; Prat, A; Rodriguez-Lescure, A; Caballero, R; Ebbert, MTW; Munarriz, B; Ruiz-Borrego, M; Bastien, RRL; Crespo, C; Davis, C; Rodriguez, CA; Lopez-Vega, JM; Furio, V; Garcia, AM; Casas, M; Ellis, MJ; Berry, DA; Pitcher, BN; Harris, L; Ruiz, A; Winer, E; Hudis, C; Stijleman, IJ; Tuck, DP; Carrasco, E; Perou, CM; Bernard, PS.

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2013; 138(2): 457-466 Nº de citas: 93 [doi:10.1007/s10549-013-2416-2]

von Minckwitz, G; Martin, M; Wilson, G; Alba, E; Schmidt, M; Biganzoli, L; Awada, A.

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2013; 85(3): 315-331 Nº de citas: 20 [doi:10.1016/j.critrevonc.2012.09.009]

Romero, A; Garcia-Saenz, JA; Fuentes-Ferrer, M; Garcia-Asenjo, JAL; Furio, V; Roman, JM; Moreno, A; de la Hoya, M; Diaz-Rubio, E; Martin, M; Caldes, T.

Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients

ANNALS OF ONCOLOGY. 2013; 24(3): 655-661 Nº de citas: 57 [doi:10.1093/annonc/mds493]

Garnett, SA; Martin, M; Jerusalem, G; Petruzelka, L; Torres, R; Bondarenko, IN; Khasanov, R; Verhoeven, D; Pedrini, JL; Smirnova, I; Lichinitser, MR; Pendergrass, K; Lindemann, JPO; Di Leo, A.

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

BREAST CANCER RESEARCH AND TREATMENT. 2013; 138(1): 149-155 Nº de citas: 17 [doi:10.1007/s10549-012-2395-8]

Ocana, A; Amir, E; Seruga, B; Martin, M; Pandiella, A.

The evolving landscape of protein kinases in breast cancer: Clinical implications

CANCER TREATMENT REVIEWS. 2013; 39(1): 68-76 Nº de citas: 19 [doi:10.1016/j.ctrv.2012.05.004]

Prat, A; Cheang, MCU; Martin, M; Parker, JS; Carrasco, E; Caballero, R; Tyldesley, S; Gelmon, K; Bernard, PS; Nielsen, TO; Perou, CM.

Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. 2013; 31(2): 203-209 Nº de citas: 497 [doi:10.1200/JCO.2012.43.4134]

Pajares, B; Pollan, M; Martin, M; Mackey, JR; Lluch, A; Gavila, J; Vogel, C; Ruiz-Borrego, M; Calvo, L; Pienkowski, T; Rodriguez-Lescure, A; Segui, MA; Tredan, O; Anton, A; Ramos, M; Camara, MD; Rodriguez-Martin, C; Carrasco, E; Alba, E.

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

BREAST CANCER RESEARCH. 2013; 15(6): Nº de citas: 70 [doi:10.1186/bcr3572]

Goss, PE; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Kaufmann, M; Boyle, F; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Chavarri-Guerra, Y; Aktan, G; Rappold, E; Williams, LS; Finkelstein, DM.

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

LANCET ONCOLOGY. 2013; 14(1): 88-96 Nº de citas: 121 [doi:10.1016/S1470-2045(12)70508-9]

Mackey, JR; Martin, M; Pienkowski, T; Rolski, J; Guastalla, JP; Sami, A; Glaspy, J; Juhos, E; Wardley, A; Fornander, T; Hainsworth, J; Coleman, R; Modiano, MR; Vinholes, J; Pinter, T; Rodriguez-Lescure, A; Colwell, B; Whitlock, P; Provencher, L; Laing, K; Walde, D; Price, C; Hugh, JC; Childs, BH; Bassi, K; Lindsay, MA; Wilson, V; Rupin, M; Houe, V; Vogel, C.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

LANCET ONCOLOGY. 2013; 14(1): 72-80 Nº de citas: 185 [doi:10.1016/S1470-2045(12)70525-9]

Khouri, MG; Douglas, PS; Mackey, JR; Martin, M; Scott, JM; Scherrer-Crosbie, M; Jones, LW.

Cancer Therapy-Induced Cardiac Toxicity in Early Breast Cancer Addressing the Unresolved Issues

CIRCULATION. 2012; 126(23): 2749-2763 Nº de citas: 195 [doi:10.1161/CIRCULATIONAHA.112.100560]

Vahdat, LT; Thomas, ES; Roche, HH; Hortobagyi, GN; Sparano, JA; Yelle, L; Fornier, MN; Martin, M; Bunnell, CA; Mukhopadhyay, P; Peck, RA; Perez, EA.

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

SUPPORTIVE CARE IN CANCER. 2012; 20(11): 2661-2668 Nº de citas: 30 [doi:10.1007/s00520-012-1384-0]

Bastien, RRL; Rodriguez-Lescure, A; Ebbert, MTW; Prat, A; Munarriz, B; Rowe, L; Miller, P; Ruiz-Borrego, M; Anderson, D; Lyons, B; Alvarez, I; Dowell, T; Wall, D; Segui, MA; Barley, L; Boucher, KM; Alba, E; Pappas, L; Davis, CA; Aranda, I; Fauron, C; Stijleman, IJ; Palacios, J; Anton, A; Carrasco, E; Caballero, R; Ellis, MJ; Nielsen, TO; Perou, CM; Astill, M; Bernard, PS; Martin, M.

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

BMC MEDICAL GENOMICS. 2012; 5: Nº de citas: 292 [doi:10.1186/1755-8794-5-44]

Serra-Rexach, JA; Jimenez, AB; Garcia-Alhambra, MA; Pla, R; Vidan, M; Rodriguez, P; Ortiz, J; Garcia-Alfonso, P; Martin, M.

Differences in the Therapeutic Approach to Colorectal Cancer in Young and Elderly Patients

ONCOLOGIST. 2012; 17(10): 1277-1285 Nº de citas: 61 [doi:10.1634/theoncologist.2012-0060]

Martin, M; Bell, R; Bourgeois, H; Brufsky, A; Diel, I; Eniu, A; Fallowfield, L; Fujiwara, Y; Jassem, J; Paterson, AHG; Ritchie, D; Steger, GG; Stopeck, A; Vogel, C; Fan, M; Jiang, Q; Chung, KR; Dansey, R; Braun, A.

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

CLINICAL CANCER RESEARCH. 2012; 18(17): 4841-4849 Nº de citas: 108 [doi:10.1158/1078-0432.CCR-11-3310]

Duenas, M; Santos, M; Aranda, JF; Bielza, C; Martinez-Cruz, AB; Lorz, C; Taron, M; Ciruelos, EM; Rodriguez-Peralto, JL; Martin, M; Larranaga, P; Dahabreh, J; Stathopoulos, GP; Rosell, R; Paramio, JM; Garcia-Escudero, R.

Mouse p53-Deficient Cancer Models as Platforms for Obtaining Genomic Predictors of Human Cancer Clinical Outcomes

PLoS One. 2012; 7(8): Nº de citas: 7 [doi:10.1371/journal.pone.0042494]

Jacquin, JP; Jones, S; Magne, N; Chapelle, C; Ellis, P; Janni, W; Mavroudis, D; Martin, M; Laporte, S.

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

BREAST CANCER RESEARCH AND TREATMENT. 2012; 134(3): 903-913 Nº de citas: 26 [doi:10.1007/s10549-011-1933-0]

von Minckwitz, G; Martin, M.

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

ANNALS OF ONCOLOGY. 2012; 23: 35-39 Nº de citas: 107 [doi:10.1093/annonc/mds193]

Romero, A; Martin, M; Oliva, B; de la Torre, J; Furio, V; de la Hoya, M; Garcia-Saenz, JA; Moreno, A; Roman, JM; Diaz-Rubio, E; Caldes, T.

Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients

ANNALS OF ONCOLOGY. 2012; 23(7): 1750-1756 Nº de citas: 34 [doi:10.1093/annonc/mdr483]